Jazz Pharmaceuticals Plc Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

1,068.90

1,197.93

1,126.11

1,045.71

897.84

1,088.17

1,054.97

Other Operating Income

0.00

Total Operating income

1,068.90

1,197.93

1,126.11

1,045.71

897.84

1,088.17

1,054.97

Raw Material Cost

306.40

323.27

297.25

278.37

259.07

287.62

269.07

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

63.30

65.81

66.77

66.06

80.91

82.20

83.36

Selling and Distribution Expenses

352.70

406.21

469.15

358.40

514.01

369.29

325.77

Other Expenses

13.27

14.81

13.14

12.39

9.97

15.83

11.66

Total Expenditure (Excl Depreciation)

855.10

943.39

964.60

826.74

953.73

897.40

794.76

Operating Profit (PBDIT) excl Other Income

213.79999999999998

254.5

161.5

219

-55.9

190.79999999999998

260.2

Other Income

157.20

21.86

25.11

4.50

18.38

48.58

9.56

Operating Profit (PBDIT)

552.40

455.56

364.87

397.48

127.36

407.77

435.00

Interest

63.30

65.81

66.77

66.06

80.91

82.20

83.36

Exceptional Items

-8.50

-2.11

-110.82

-892.97

8.61

-23.93

14.40

Gross Profit (PBDT)

762.50

874.66

828.86

767.34

638.77

800.56

785.90

Depreciation

181.40

179.17

178.25

174.01

164.87

168.42

165.23

Profit Before Tax

299.20

208.47

9.04

-735.55

-109.81

133.22

200.81

Tax

6.10

4.96

-242.42

-17.17

-17.81

-57.91

-14.53

Provisions and contingencies

0.00

Profit After Tax

293.10

203.45

251.41

-718.47

-92.54

191.12

215.06

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

293.10

203.45

251.41

-718.47

-92.54

191.12

215.06

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

293.10

203.45

251.41

-718.47

-92.54

191.12

215.06

Equity Capital

0.00

Face Value

0.0

Reserves

4,532.30

4,318.58

3,959.03

3,706.36

4,174.89

4,093.76

4,171.07

Earnings per share (EPS)

4.43

3.21

4.08

-11.74

-1.52

3.11

3.4

Diluted Earnings per share

4.43

3.21

4.08

-11.74

-1.52

3.11

3.4

Operating Profit Margin (Excl OI)

20.0%

21.25%

14.34%

20.94%

-6.23%

17.53%

24.67%

Gross Profit Margin

44.96%

32.36%

16.63%

-53.7%

6.13%

27.72%

34.7%

PAT Margin

27.42%

16.98%

22.33%

-68.71%

-10.31%

17.56%

20.38%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Mar 2026 is 19.06% vs -0.47% in Mar 2025

Consolidate Net Profit

YoY Growth in quarter ended Mar 2026 is 416.86% vs -533.56% in Mar 2025

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 262.57% vs -54.51% in Mar 2025

Interest

YoY Growth in quarter ended Mar 2026 is -21.76% vs -10.01% in Mar 2025

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Compare Quarterly Results Of Jazz Pharmaceuticals Plc With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(USD)

Change(%)

Net Sales

1,068.90

2.00

1,066.90

53,345.00%

Other Operating Income

0.00

Total Operating income

1,068.90

2.00

1,066.90

53,345.00%

Raw Material Cost

306.40

1.39

305.01

21,943.17%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

63.30

0.00

63.30

Selling and Distribution Expenses

352.70

174.38

178.32

102.26%

Other Expenses

13.27

16.54

-3.27

-19.77%

Total Expenditure (Excl Depreciation)

855.10

341.15

513.95

150.65%

Operating Profit (PBDIT) excl Other Income

213.80

-339.15

552.95

163.04%

Other Income

157.20

51.61

105.59

204.59%

Operating Profit (PBDIT)

552.40

-286.85

839.25

292.57%

Interest

63.30

0.00

63.30

Exceptional Items

-8.50

-2.82

-5.68

-201.42%

Gross Profit (PBDT)

762.50

0.61

761.89

124,900.00%

Depreciation

181.40

0.69

180.71

26,189.86%

Profit Before Tax

299.20

-290.37

589.57

203.04%

Tax

6.10

23.33

-17.23

-73.85%

Provisions and contingencies

0.00

Profit After Tax

293.10

-265.89

558.99

210.23%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

293.10

-265.89

558.99

210.23%

Share in Profit of Associates

0.00

Minority Interest

0.00

-47.81

47.81

100.00%

Other related items

0.00

Consolidated Net Profit

293.10

-313.70

606.80

193.43%

Equity Capital

0.00

Face Value

0.00

Reserves

4,532.30

4,269.26

263.04

6.16%

Earnings per share (EPS)

4.43

-0.38

4.81

1,265.79%

Diluted Earnings per share

4.43

-0.38

4.81

1,265.79%

Operating Profit Margin (Excl OI)

20.00%

-16,966.13%

0.00

16,986.13%

Gross Profit Margin

44.96%

-14,491.15%

0.00

14,536.11%

PAT Margin

27.42%

-13,301.20%

0.00

13,328.62%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 106.89 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -10.77% vs 6.38% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 19.06% vs -0.47% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 29.31 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 44.03% vs -19.05% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 416.86% vs -533.56% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 39.52 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -8.88% vs 27.63% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 262.57% vs -54.51% in Mar 2025

Quarterly - Interest

Interest 6.33 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -3.80% vs -1.50% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -21.76% vs -10.01% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 20.00%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025